Colon cancer remains a significant global health burden, accounting for approximately 10% of all cancer cases worldwide and ranking as the second leading cause of cancer‐related mortality. Despite advances in treatment, the 5‐year survival rate for late‐stage colorectal cancer remains as low as 14%, whereas early detection can improve survival to over 90%. This review explores recent advancements in image‐based analyses for the morphology and staging of colon cancer, focusing on key imaging modalities, including colonoscopy, computed tomography (CT), magnetic resonance imaging (MRI), endoscopic ultrasound (EUS), histopathological analysis, and the integration of artificial intelligence (AI) and machine learning (ML) algorithms. A systematic literature review was conducted using peer‐reviewed studies from databases such as PubMed, Scopus, and IEEE Xplore. Selection criteria included studies published within the past decade that evaluated imaging techniques for colon cancer detection, staging, and treatment planning. AI and ML applications in colon cancer imaging were also examined, with an emphasis on their diagnostic accuracy, staging precision, and impact on clinical decision‐making. Findings indicate that AI‐assisted imaging techniques enhance lesion detection sensitivity (88%–94%) and improve staging accuracy compared to conventional radiology methods. AI models have also demonstrated superior predictive capabilities in treatment response and prognosis, with deep learning–based algorithms achieving over 90% accuracy in 5‐year survival prediction. Despite these advancements, challenges persist, including interobserver variability, dataset biases, regulatory concerns, and the need for standardized AI validation protocols. Addressing these challenges requires interdisciplinary collaboration among clinicians, researchers, and policymakers to refine AI algorithms, develop standardized imaging protocols, and ensure equitable AI applications across diverse populations. By leveraging advancements in imaging and AI‐driven analysis, colon cancer diagnosis and management can be significantly improved, ultimately enhancing early detection rates, treatment personalization, and patient survival outcomes.

Background/Objectives: The COVID-19 pandemic has significantly impacted global health. However, Africa has reported relatively low numbers of cases and fatalities. Although the pandemic has largely receded, the reasons for its milder course on the African continent have not yet been fully clarified. This study explored the hypothesis that helminth co-infections may have contributed to these observations. Methods: A retrospective cohort study was conducted using 104 plasma samples collected during the third wave of the pandemic in the Ashanti Region of Ghana. Luminex assays were used to measure SARS-CoV-2-specific IgA and IgG, neutralizing antibodies, systemic cytokines and helminth-specific IgG. Results: The results indicated that the highest cumulative seroprevalence of helminths (61.5%) was observed in asymptomatic COVID-19 patients. In comparison, mild and moderate patients had helminth seropositivity rates of 43.8% and 34.5%, respectively, which were 1.4 and 1.8 times lower than those of the asymptomatic group, respectively. Notably, the two severe COVID-19 cases investigated were seronegative for all three of the helminths tested. Strikingly, co-exposure resulted in lower SARS-CoV-2-specific IgA/IgG expression and reduced neutralization potential. However, co-seropositive individuals for helminths and SARS-CoV-2 exhibited a higher expression of Th2 cytokines and IL-10 over Th1 cytokines compared to SARS-CoV-2-positive individuals alone. Conclusion: These data suggest that co-exposure to helminths could mitigate the severity of COVID-19 outcomes by reducing the Th1 and Th17 responses; this highlights the potential protective role of helminthiasis against severe COVID-19. These findings provide valuable insights for the development of public health policies in helminth-endemic regions and underscore the importance of considering helminth co-infections in managing viral infections. It also offers a plausible explanation for the milder disease severity observed in helminth-endemic regions while raising critical considerations regarding vaccine efficacy, as helminth-induced immune modulation may influence the magnitude and quality of vaccine-induced immune responses.

The COVID-19 pandemic has significantly impacted global health. However, Africa has reported relatively low numbers of cases and fatalities. Although the pandemic has largely receded, the reasons for its milder course on the African continent have not yet been fully clarified. This study explored the hypothesis that helminth co-infections may have contributed to these observations. A retrospective cohort study was conducted using 104 archived plasma samples collected during the third wave of the pandemic in the Ashanti Region of Ghana. ELISA and Luminex assays were used to measure SARS-CoV-2-specific IgA and IgG, neutralizing antibodies, and helminth-specific IgG levels. The results indicated that the highest cumulative seroprevalence of helminths (61.5%) was observed in asymptomatic SARS-CoV-2-infected individuals. In comparison, mild and moderate COVID-19 patients had helminth seropositivity rates of 43.8% and 34.5%, respectively, which were 1.4 and 1.8 times lower than those of the asymptomatic group, respectively. Notably, the two severe COVID-19 cases investigated were seronegative for all three helminths tested. Strikingly, co-exposure resulted in lower SARS-CoV-2-specific IgA/IgG expression and reduced neutralization potential. However, in the plasma of individuals co-seropositive for helminths and SARS-CoV-2, a significantly higher expression of Th2 cytokines and IL-10 over Th1 was observed compared to those who were SARS-CoV-2 positive alone. These data suggest that co-exposure to helminths could mitigate severe COVID-19 outcomes by reducing the Th1 and Th17 responses. Our study highlights the potential protective role of helminth co-infection against severe COVID-19, suggesting that helminth-induced immune modulation may improve clinical outcomes. These findings provide valuable insights for public health policies in helminth-endemic regions and underscore the importance of considering helminth co-infections in managing viral infections.

Background: The interaction between helminth and viral infections has important implications for understanding viral disease outcomes and vaccine efficacy in helminth-endemic regions. We previously demonstrated that helminth seropositivity is associated with reduced Th1/Th17 cytokine levels and reduced COVID-19 severity; however, the underlying immunological mechanisms remain unclear. This study further investigated these mechanisms by assessing how helminth antigens influence SARS-CoV-2-induced T-cell responses in individuals infected with filarial parasites in vitro. Methods: Peripheral blood mononuclear cells (PBMCs) from 43 participants, including Onchocerca volvulus-infected individuals, filarial lymphedema patients, and non-endemic controls, were stimulated in vitro with SARS-CoV-2 peptides and Ascaris lumbricoides antigens. Results: Fluorescence-activated cell sorting analysis showed a significant reduction in SARS-CoV-2-induced CD154 expression on CD4⁺ T cells but an increase on CD8⁺ T cells in O. volvulus-infected participants (p < 0.0001). A. lumbricoides antigens alone did not induce significant T-cell activation in O. volvulus-infected individuals. However, SARS-CoV-2 peptides strongly activated CD4⁺CD154⁺ T cells response (p = 0.0074), but co-stimulation with A. lumbricoides antigens markedly reduced CD3⁺ and CD4⁺CD154⁺ T-cell expression frequencies (p = 0.0329 and p = 0.0452). A. lumbricoides-specific IgG correlated inversely with SARS-CoV-2-induced CD4⁺CD154⁺ expression (r = −0.6025, p = 0.0049), whereas SARS-CoV-2-specific IgG was positively associated with CD4⁺CD154⁺ and CD8⁺CD154⁺ T-cell responses (β = 0.532, p = 0.016 and β = 0.509, p = 0.022). Conclusion: These findings demonstrate that helminth antigens modulate functional SARS-CoV-2-induced T-cell responses, offering a potential mechanism through which helminth co-infections shape antiviral immunity, vaccine efficacy, and clinical disease outcomes.

Background: The lack of a short-course of safe and effective macrofilaricidal therapy for lymphatic filariasis (LF) hinders elimination efforts, especially in the endgame scenario. Preclinical studies in mice demonstrated that high-dose rifampicin (RIF) plus albendazole (ALB) produced macrofilaricidal effects within seven days, prompting this randomised, open-label, parallel-group, interventional phase II pilot trial to determine the efficacy of high-dose RIF plus ALB against LF in humans. Methods: In three LF-endemic districts of Ghana’s Upper East Region, circulating filarial antigen (CFA)-positive individuals aged 18 to 55 years identified using the Alere Filariasis Test Strip were enrolled into the study. The participants were randomised through a centralized computer-generated randomisation into four treatment arms. They were treated according to the arm they were assigned to and followed up at 4-, 6-, 12-, and 18-months post-treatment to monitor changes in CFA status and levels, as well as adverse events. Outcome assessors were blinded to minimize assessment bias. Results: A total of 69 eligible participants were randomised into four treatment arms: RIF (35 mg/kg/day) + ALB (400 mg/day) for 7 days (n = 17), RIF (35 mg/kg/day) + ALB (400 mg/day) for 14 days (n = 18), ALB alone for 14 days (n = 17), and an untreated controlled group participating in standard mass drug administration (n = 17). All regimens were well tolerated, with no serious adverse events. Even though CFA positivity declined across all groups, with maximal reductions at 18 months, the RIF + ALB 7-day regimen consistently showed the highest decline, while ALB alone was the least effective. RIF + ALB groups exhibited early antigen decline by 4 months, unlike comparator groups, where reductions occurred from 12 months. Conclusions: These findings suggest macrofilaricidal activity of high-dose RIF plus ALB, supporting further trials in larger, microfilaraemic populations. The trial was registered in the Pan African Clinical Trials Registry on 9 September 2020 under the code PACTR202009704006025.Funding was by the European and Developing Countries Clinical Trials Partnership 2 (EDCTP2), with grant code TMA2018SF-2451-ASTAWOL, and by the German Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung-BMBF) under agreement with Gesellschaft für Internationale Zusammenarbeit (GIZ) through agreement number: 81204851.

Introduction Filarial lymphedema (elephantiasis) is a chronic, disabling condition affecting over 15 million people worldwide. Acute adenolymphangitis (ADL) attacks, characterized by fever, chills, and painful inflammation, contribute substantially to morbidity. These episodes are thought to be precipitated by bacterial entry through leg wounds or lesions, yet evidence on specific triggers and comorbidities remains limited. Understanding these factors is essential for improving patient care and supporting the World Health Organization’s Global Programme to Eliminate Lymphatic Filariasis (GPELF). Methods A longitudinal cohort study was conducted in northern Ghana involving 162 participants. The study monitored ADL attacks, documented leg injuries, and assessed comorbidities among individuals with lymphedema. Results Of the 162 participants, 17 (10.2%) experienced ADL attacks during follow-up. Blood cultures were consistently negative for bacteria, fungi, and yeasts. Most attacks (82.4%) occurred following injuries to the lymphedematous legs. Wounds or lesions were observed in 22.2% of participants, and among these, 36.1% were diabetic. Overall, comorbidities included hypertension (29.6%) and overweight/obesity (30.2%). Multimorbidity was present in 6.2% of participants, underscoring the complexity of care needs in this population. Conclusion Current findings indicate that leg injuries are the predominant triggers of ADL attacks in this population, while diabetes, hypertension, and other comorbidities pose additional challenges for management. These insights highlight the need for strengthened hygiene-based interventions, wound management strategies, and integrated approaches to comorbidity care, contributing to improved morbidity control within GPELF.